Sort   by:  
 Page size 
MetabolomicsAdjunctive ibuprofen in pre-extensively drug-resistant and extensively drug-resistant tuberculosis: a Phase IIA open-label pilot clinical trial

Drug-resistant tuberculosis (TB) remains a major global health challenge. Host-directed therapies (HDTs) aim to limit tissue damage, shorten treatment, and improve outcomes by modulating immune responses. We evaluated the safety and potential efficacy of adjunctive ibuprofen an inexpens...

2026-05-28 | MTBLS13376 | MetaboLights
MetabolomicsUntargeted 1 H NMR-based metabolomics unveils distinct circulating biochemical signatures between treatment-resistant and non-treatment-resistant Schizophrenia patients: a pilot study

Schizophrenia is a severe psychiatric disorder impacting roughly 1% of individuals. The effectiveness of antipsychotic therapy greatly varies, with around 30% of patients categorised as treatment-resistant (TRS). TRS is characterised by a lack of response to at least two clinical trials invo...

2025-10-01 | MTBLS12709 | MetaboLights
ProteomicsProteomic Analysis of Drug-resistant Mycobacteria
Tuberculosis, caused by the pathogen Mycobacterium tuberculosis is a worldwide public health threat. Mycobacterium tuberculosis is capable of resisting of various stresses in host cells including high levels of ROS and copper ions. To better understand the resistance mechanisms of mycobacteria to co...
ORGANISM(S): Corynebacterineae 
2016-04-13 | PXD001989 | Pride
Copper resistant Drug resistant Mycobacteria 
MetabolomicsAspartate potentiates tobramycin against multidrug-resistant Edwardsiella tarda through enhancing proton motive force and membrane permeability

The antibiotic susceptibility/resistance of bacteria is influenced by their metabolic states. In tobramycin-resistant Edwardsiella tarda (LTB4-RToB), a dynamic metabolic state is observed, characterized by a general reduction in most metabolites as the minimum inhibitory concentration (MIC) incre...

2025-07-31 | MTBLS12725 | MetaboLights
GenomicsRerep-Seq of copper resistant yeast
Rerep-Seq of copper resistant yeast
PRJNA698368 | ENA
TranscriptomicsRole of an archaeal PitA transporter in the copper and arsenic resistance of Metallosphaera sedula an extreme thermoacidophile
Thermomacidophilic archaea, such as Metallosphaera sedula, are lithoautotrophs that occupy metal-rich environments. In previous studies, a M. sedula mutant lacking the primary copper efflux transporter, CopA, became copper sensitive. In contrast, the basis for supra-normal copper resistance remained...
ORGANISM(S): Metallosphaera sedula DSM 5348 
2014-07-10 | E-GEOD-59253 | biostudies-arrayexpress
UnknownEvaluation of copper alloys for reducing infection by methicillin resistant Staphylococcus aureus and vancomycin resistant Enterococcus faecium in intensive care unit and in vitro.
Not available
S-EPMC8435501 | biostudies-literature
TranscriptomicsTranscription profiling of yeast haploid and heterozygous essential deletion pools treated with compounds involved in copper metabolism
The haploid and the heterozygous essential S.cerevisiae deletion pools were grown in the presence of compounds that cause copper metabolism phenotypes in zebrafish. These experimental samples were hybridized against DMSO control samples. The resulting hybridization pattern informs about sensitive an...
ORGANISM(S): Saccharomyces cerevisiae 
2010-02-20 | E-TABM-922 | biostudies-arrayexpress
TranscriptomicsPromoter methylation data: OHT/ICI-sensitive vs. -resistant cell lines
MCF7 breast cancer cell lines: drug-resistant (OHT and ICI) cell lines vs. drug-sensitive (wild type) cell lines. Assessment of association between gene expression and methylation. Two comparisons: OHT-resistant vs. wild type, and ICI-resistant vs. wild type. OHT: 4-hydroxytamoxifen ICI: fulvestran...
ORGANISM(S): Homo sapiens 
2011-10-04 | E-GEOD-25519 | biostudies-arrayexpress
TranscriptomicsAmmonium tetrathiomolybdate treatment targets the copper transporter ATP7A in cisplatin-resistant breast cancer TM and cisplatin sensitize resistant breast cancer.
Chemotherapy resistance presents a major hurdle for cancer treatment. We proposed to identify the molecular changes through which breast cancer cells evolve resistance to conventional treatment, here cisplatin, so targeted therapy can be developed. Candidate approach RNAi screening was combined with...
ORGANISM(S): Homo sapiens 
2017-06-19 | GSE77515 | GEO
Sort   by:  
 Page size